RxDoctor Payments Data

George Declerk, MD

Family Medicine · Rogers, ARNPI 1205037611

Payments from drug & device makers

$1,328in general payments, 2019–2025

Across 41 payments — averaging $32.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$616
  • AbbVie$237
  • Pfizer$156
  • AstraZeneca$133
  • Inari Medical, Inc.$98
  • Novo Nordisk$41
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$1,328100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)28$616
AbbVie(2 entities)4$237
Pfizer3$156
AstraZeneca2$133
Inari Medical, Inc.1$98
Novo Nordisk1$41
Axsome Therapeutics, Inc.1$33
Abbott1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,328 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$101,152
Medicare patients
217
Services billed
1,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol93$89,609
EliquisApixaban62$55,292
OzempicSemaglutide43$54,679
JardianceEmpagliflozin59$50,063
MounjaroTirzepatide38$41,969
XareltoRivaroxaban41$31,111
TradjentaLinagliptin32$29,634
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,994
Nurtec OdtRimegepant Sulfate13$21,475
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$18,778
Breo ElliptaFluticasone/Vilanterol15$8,217
MyrbetriqMirabegron16$8,200
DapagliflozinDapagliflozin Propanediol12$7,021
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,906
SymbicortBudesonide/Formoterol Fumarate14$5,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$133$114,054135 claims
PfizerEliquis, Nurtec Odt$156$76,76775 claims
Novo NordiskOzempic$41$54,67943 claims
AbbVieSynthroid$237$3,53031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →